We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Electroceutical Device Eases Chronic Back and Leg Pain

By HospiMedica International staff writers
Posted on 16 Dec 2014
A new injectable neuromodulation device powered by an externally worn transmitter aids in the relief of chronic back and leg pain.

The Stimwave Freedom Spinal Cord Stimulation (SCS) system is based on a tiny injectable microchip that delivers small pulses of energy to electrodes near surrounding nerves, triggering a reaction that enables the brain to remap specific pain signals, thus providing pain relief. The stimulator, which is so narrow (1.3 mm) that it can be implanted through a standard needle, eliminates the need for long electrical leads necessary in pacemaker-like devices. Containing 4 electrode arrays, the stimulator is fixed in place by a suture sleeve cap anchor, serving as a permanent, long-term device.

Image: The Freedom Spinal Cord Stimulation (SCS) system (Photo courtesy of Stimwave Technologies).
Image: The Freedom Spinal Cord Stimulation (SCS) system (Photo courtesy of Stimwave Technologies).

The SCS is powered by a wearable antenna assembly (WAA) that uses wireless radiofrequency (RF) signals; wireless Bluetooth technology is also used to program the WAA with specific stimulation parameters. For added safety, the neurostimulator only accepts communication from a specific WAA. The system also features the ability to allow the patient to have a whole body 3 T or 1.5 T magnetic resonance imaging (MRI) scan, without removing the implant. The Stimwave Freedom SCS system is a product of Stimwave Technologies (Miami Beach, FL, USA), and has been approved by the US Food and Drug Administration (FDA).

“This technology is no longer an academic-type science experiment, but a real, viable innovation that can immediately start being utilized by patients in pain,” said Laura Tyler Perryman, MSc, MBA, co-inventor of the SCS system and CEO and chairman of Stimwave Technologies. “Historically with SCS, dependency on pain medications can be drastically reduced or even eliminated.”

“I am extremely excited about this new technology developed by Stimwave and recent clearance by the FDA,” said David Kloth, MD, medical director of the Connecticut Pain Care Center and author of the book Pain Wise. “Now people in pain will have additional options including the ability to receive a permanent implant with a far less invasive and complicated surgery, while avoiding the cumbersome long-term issues with recharging, as is the case today with other systems.”

SCS, in the simplest form, consists of stimulating electrodes implanted in the epidural space. It has notable analgesic properties and, at the present, is used mostly in the treatment of failed back surgery syndrome, complex regional pain syndrome, and refractory pain due to ischemia.

Related Links:

Stimwave Technologies



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Vertebral Body Replacement System
Hydrolift
New
X-ray Diagnostic System
FDX Visionary-A

Latest Critical Care News

Ablation Treatment Better Than Medication for Heart Attack Survivors

Cranial Accelerometry Headset Enables Timely and Accurate Prehospital Detection of LVO Strokes

Ingestible Capsule Pump Drugs Directly into Walls of GI Tract